Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Future strategies in second line treatment
    Meeting Abstract

    Riely, G.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers
    Journal Article

    Mondaca, S.; Offin, M.; Borsu, L.; Myers, M.; Josyula, S.; Makhnin, A.; Shen, R.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; more...
    Acta Oncologica (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas
    Meeting Abstract

    Whipple, S.; Martin, A.; Martinec, M.; Arbour, K. C.; Seshan, V. E.; Riely, G. J.; Crane, G.; Shen, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Shaw, A. T.; Martini, J. F.; Besse, B.; Bauer, T. M.; Lin, C. C.; Soo, R. A.; Riely, G. J.; Ou, S. H. I.; Abbattista, A.; Toffalorio, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A. J.; Chan, J. M.; Rizvi, H.; Rekhtman, N.; Daneshbod, Y.; Kubota, D.; Chang, J. C.; Arcila, M. E.; Ladanyi, M.; Somwar, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC
    Meeting Abstract

    Riely, G. J.; Lovly, C. M.; Messina, C. G. M.; Bienert, S.; Alexander, K.; Pao, W.; Baxi, S.; Doebele, R. C.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs
    Meeting Abstract

    Lin, J. J.; Schoenfeld, A. J.; Zhu, V. W.; Yeap, B. Y.; Chin, E.; Rooney, M.; Plodkowski, A. J.; Digumarthy, S.; Dagogo-Jack, I.; Gainor, J. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions
    Meeting Abstract

    Janne, P. A.; Neal, J. W.; Camidge, D. R.; Spira, A. I.; Piotrowska, Z.; Horn, L.; Costa, D. B.; Tsao, A. S.; Patel, J. D.; Gadgeel, S. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save